These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 32487421)

  • 41. Association of Progressive Supranuclear Palsy Rating Scale with Progressive Supranuclear Palsy Quality of Life Scale.
    Pantelyat A; Higginbotham L; Rosenthal L; Lanham D; Nesspor V; AlSalihi M; Bang J; Wang J; Albert M
    Neurodegener Dis; 2020; 20(4):139-146. PubMed ID: 33789283
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging Diagnostic and Therapeutic Strategies for Tauopathies.
    Coughlin D; Irwin DJ
    Curr Neurol Neurosci Rep; 2017 Sep; 17(9):72. PubMed ID: 28785992
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy.
    Shoeibi A; Olfati N; Litvan I
    Expert Opin Investig Drugs; 2018 Apr; 27(4):349-361. PubMed ID: 29602288
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gradient subthalamic neurodegeneration and tau pathology in the hypoglossal nucleus as essential pathological markers of progressive supranuclear palsy - Richardson syndrome.
    Homma T; Mochizuki Y; Hara M; Kamei S; Mizutani T; Takubo H; Isozaki E; Takahashi M; Komori T; Hao H
    Rev Neurol (Paris); 2020 May; 176(5):353-360. PubMed ID: 32247606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia.
    Kanazawa M; Tada M; Onodera O; Takahashi H; Nishizawa M; Shimohata T
    Parkinsonism Relat Disord; 2013 Dec; 19(12):1149-51. PubMed ID: 23916652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progressive supranuclear palsy.
    Kent A
    Nurs Stand; 2013 Aug 21-27; 27(51):48-57; quiz 58. PubMed ID: 23965099
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Role of MicroRNAs in Progressive Supranuclear Palsy-A Systematic Review.
    Ćwiklińska A; Procyk G; Koziorowski D; Szlufik S
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125813
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.
    Litvan I; Mangone CA; McKee A; Verny M; Parsa A; Jellinger K; D'Olhaberriague L; Chaudhuri KR; Pearce RK
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):615-20. PubMed ID: 8648326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebral Tau Deposition in Comorbid Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis: An [18F]-Flortaucipir and 7T MRI Study.
    Cheong I; Du Y; Smith G; Hua J; Li X; Pantelyat A
    Neurodegener Dis; 2023; 23(3-4):35-42. PubMed ID: 38527450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progressive supranuclear palsy and corticobasal degeneration: Diagnostic challenges and clinicopathological considerations.
    Eusebio A; Koric L; Félician O; Guedj E; Ceccaldi M; Azulay JP
    Rev Neurol (Paris); 2016; 172(8-9):488-502. PubMed ID: 27561438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and neuroimaging features of the progressive supranuclear palsy- corticobasal degeneration continuum.
    Whitwell JL
    Curr Opin Neurol; 2023 Aug; 36(4):283-290. PubMed ID: 37462045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Progressive supranuclear palsy; an unusual form of parkinsonism].
    Donker Kaat L; Boon AJ; Heutink P; van Swieten JC
    Ned Tijdschr Geneeskd; 2004 Mar; 148(11):519-23. PubMed ID: 15054950
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.
    Litvan I; Agid Y; Calne D; Campbell G; Dubois B; Duvoisin RC; Goetz CG; Golbe LI; Grafman J; Growdon JH; Hallett M; Jankovic J; Quinn NP; Tolosa E; Zee DS
    Neurology; 1996 Jul; 47(1):1-9. PubMed ID: 8710059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: a forensic autopsy series.
    Yoshida K; Hata Y; Kinoshita K; Takashima S; Tanaka K; Nishida N
    Acta Neuropathol; 2017 May; 133(5):809-823. PubMed ID: 28064358
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A clinicopathological study of vascular progressive supranuclear palsy: a multi-infarct disorder presenting as progressive supranuclear palsy.
    Josephs KA; Ishizawa T; Tsuboi Y; Cookson N; Dickson DW
    Arch Neurol; 2002 Oct; 59(10):1597-601. PubMed ID: 12374498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early Stage of Progressive Supranuclear Palsy: A Neuropathological Study of 324 Consecutive Autopsy Cases.
    Nogami A; Yamazaki M; Saito Y; Hatsuta H; Sakiyama Y; Takao M; Kimura K; Murayama S
    J Nippon Med Sch; 2015; 82(6):266-73. PubMed ID: 26823029
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Progressive supranuclear palsy.
    Boeve BF
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S192-4. PubMed ID: 22166432
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy.
    Brendel M; Barthel H; van Eimeren T; Marek K; Beyer L; Song M; Palleis C; Gehmeyr M; Fietzek U; Respondek G; Sauerbeck J; Nitschmann A; Zach C; Hammes J; Barbe MT; Onur O; Jessen F; Saur D; Schroeter ML; Rumpf JJ; Rullmann M; Schildan A; Patt M; Neumaier B; Barret O; Madonia J; Russell DS; Stephens A; Roeber S; Herms J; Bötzel K; Classen J; Bartenstein P; Villemagne V; Levin J; Höglinger GU; Drzezga A; Seibyl J; Sabri O
    JAMA Neurol; 2020 Nov; 77(11):1408-1419. PubMed ID: 33165511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emerging drugs for progressive supranuclear palsy.
    Giagkou N; Stamelou M
    Expert Opin Emerg Drugs; 2019 Jun; 24(2):83-92. PubMed ID: 31007097
    [No Abstract]   [Full Text] [Related]  

  • 60. Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype.
    Koga S; Kouri N; Walton RL; Ebbert MTW; Josephs KA; Litvan I; Graff-Radford N; Ahlskog JE; Uitti RJ; van Gerpen JA; Boeve BF; Parks A; Ross OA; Dickson DW
    Acta Neuropathol; 2018 Sep; 136(3):389-404. PubMed ID: 29926172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.